Global Needle-Free Drug Delivery Devices Market Report 2024

The needle-free drug delivery devices market size has grown exponentially in recent years. It will grow from $14.99 billion in 2023 to $16.7 billion in 2024 at a compound annual growth rate (CAGR) of 11.4%. The growth observed during the historic period can be attributed to several factors, including the increased prevalence of chronic diseases, heightened demand for painless drug delivery methods, a growing geriatric population, emphasis on patient compliance and safety, regulatory support for needle-free technologies, and expansion within the pharmaceutical industry.

The needle-free drug delivery devices market size is expected to see exponential growth in the next few years. It will grow to $25.88 billion in 2028 at a compound annual growth rate (CAGR) of 11.6%. The anticipated growth in the forecast period can be attributed to several factors, including increasing demand for painless medication administration, a growing emphasis on patient-centric healthcare solutions, expanding applications in pediatric and geriatric populations, rising prevalence of chronic diseases requiring frequent injections, technological advancements enhancing device efficiency and usability, expanding access to healthcare in emerging markets, and growing investments in research and development for innovative delivery systems. Major trends expected during this period include increased adoption of wearable and connected devices, the emergence of novel microfluidic technologies, a growing focus on pediatric-friendly needle-free solutions, integration of artificial intelligence and machine learning algorithms, and expanding applications in home healthcare settings.

The rise in diabetes prevalence is anticipated to drive the expansion of the needle-free drug delivery device market in the foreseeable future. Diabetes, characterized by elevated blood sugar levels due to insufficient insulin production or ineffective insulin utilization, persists as a significant health concern. Sedentary lifestyles, poor dietary habits, genetic factors, urbanization, aging populations, limited healthcare access, and increasing obesity rates contribute to the growing incidence of diabetes globally. Needle-free drug delivery devices offer an alternative to traditional injections for administering insulin in diabetes management. These devices utilize technologies such as jet injectors or transdermal patches to deliver insulin through the skin without needles, mitigating the discomfort and anxiety associated with injections and improving patient comfort. For instance, the International Diabetes Federation reported in July 2021 that the projected number of individuals living with diabetes is expected to reach 643 million by 2030 and 783 million by 2045, highlighting the upward trend in diabetes prevalence. Consequently, the rising prevalence of diabetes is propelling the growth of the needle-free drug delivery device market.

Prominent companies in the needle-free drug delivery device market are concentrating on innovative solutions such as dual-chamber inhalers to enhance effectiveness and ease of administration, addressing the evolving needs of patients and healthcare providers. A dual-chamber inhaler comprises two compartments capable of holding different medications separately, facilitating the combination of multiple drugs in a single device for streamlined treatment and enhanced patient convenience. For instance, Berry Global, a US-based plastic manufacturing company, introduced the BerryHaler in April 2024, a state-of-the-art dry powder inhaler (DPI) designed to revolutionize patient-centered healthcare solutions. Equipped with a dose counter, this dual-chamber inhaler ensures precise medication administration and features an all-plastic construction devoid of metal parts, ideal for complex inhalation treatments. Advanced functionalities such as a bi-directional mouthpiece cover for convenience and hygiene, along with audible signals indicating proper usage, enhance user experience. The integrated dose counter facilitates accurate monitoring of medication usage, minimizing dosage errors.

In May 2022, Halozyme Therapeutics Inc., a US-based biotechnology company, acquired Antares Pharma Inc. for $960 million, aiming to strengthen its position as a leading drug delivery company. Leveraging Antares' auto-injector platform and specialty commercial business, Halozyme expands its strategy to include specialty products, accelerating long-term revenue growth. Antares Pharma Inc., a US-based pharmaceutical company, specializes in developing needle-free injectors used for insulin delivery in diabetes treatment.

Major companies operating in the needle-free drug delivery devices market are Pfizer Inc., Merck & Co. Inc., Bayer AG, 3M Company, Medtronic plc, Novo Nordisk AS, Becton, Dickinson and Company, Endo International plc, Insulet Corporation, Purdue Pharma L.P., Antares Pharma Inc., MannKind Corporation, Med-Jet Inc., Portal Instruments, PharmaJet, Inovio Pharmaceuticals, Inc., National Medical Products Inc., Mika Medical Co. Ltd., Medical International Technology Inc. (MTI), NanoPass Technologies Ltd., PenJet Corporation, Akra Dermojet S.A., NuGen Medical Devices Inc., Crossject SA, Injex Pharma AG.

North America was the largest region in the needle-free drug delivery devices market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the needle-free drug delivery devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the needle-free drug delivery devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Needle-free drug delivery devices are medical tools designed to administer medication without the use of traditional needles. They provide an alternative method for delivering drugs, vaccines, or therapeutic agents into the body through the skin or mucosal membranes, aiming to reduce patient discomfort and the risk of needle-related injuries.

The primary types of needle-free drug delivery devices include inhalers, jet injectors, novel needles, transdermal patches, and others. Inhalers are portable devices that deliver medication directly into the lungs through a mist or spray. They find applications in various areas such as pain management, vaccine delivery, pediatric injections, insulin delivery, among others, and are utilized by a range of end-users including hospitals and clinics, as well as home healthcare settings.

The needle-free drug delivery devices market research report is one of a series of new reports that provides needle-free drug delivery devices market statistics, including needle-free drug delivery devices industry global market size, regional shares, competitors with a needle-free drug delivery devices market share, detailed needle-free drug delivery devices market segments, market trends and opportunities, and any further data you may need to thrive in the needle-free drug delivery devices industry. This needle-free drug delivery devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The needle-free drug delivery devices market consists of sales of nasal sprays, buccal patches, and oral inhalers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.